Skip to content

Unlock the Cell: Castleman's Disease Flow Cytometry Study

Unlock the Cell: Intracellular Inflammatory Pathways and Flow Cytometry Study for Castleman's Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02853968
Enrollment
130
Registered
2016-08-03
Start date
2016-02-29
Completion date
2019-03-30
Last updated
2020-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiofollicular Lymph Hyperplasia, Angiofollicular Lymphoid Hyperplasia, Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, GLNH, Hyperplasia

Keywords

Unlock the Cell, Castleman's Disease, CD, Castleman Disease, MCD, iMCD, Angiofollicular Lymph Hyperplasia, multicentric Castleman's disease, multicentric Castleman disease, idiopathic multicentric Castleman disease

Brief summary

Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction. In this study, we will investigate inflammatory markers, cells, and signaling pathways in prospectively collected blood samples and/or buccal swabs or saliva using biochemical and RT-PCR techniques, proteomics, genomics, immunohistochemistry, storage for future use, cell culture treated with external stimuli, flow cytometry, and other molecular tests

Detailed description

This is a University of Pennsylvania-sponsored project that is supported by the Castleman Disease Collaborative Network and the patients/loved one's group Castleman's Warriors (Castleman's Awareness and Research Effort). Castleman Disease (CD) is a rare and poorly understood lymphoproliferative disease. The multicentric CD subtype (MCD) involves enlarged lymph nodes in multiple regions of the body and can be fatal if untreated. MCD patients demonstrate acute inflammatory crisis due to upregulation of inflammatory agents most notably IL-6 and VEGF followed by multiple organ failure and death. Unlock the Cell aims to identify the pathways the disease takes through flow cytometry studies. The purpose of the CD Research study is to collect blood samples and/or buccal swabs or saliva samples and medical information of MCD patients and compare them to control samples so researchers can understand the causes of MCD, and design treatments based on our findings. In this study, the investigators will analyze inflammatory markers, cells, and signaling pathways in prospectively collected blood samples using biochemical and RT-PCR techniques, proteomics, genomics, immunohistochemistry, storage for future use, cell culture treated with external stimuli, flow cytometry, and other molecular tests. A secondary aim is to collect excess stored tissue samples (e.g., lymph node, bone marrow) from previous procedures and store these samples along with unused blood samples for future research purposes to be performed at the University of Pennsylvania or shared with other Castleman disease researchers and biobanks.

Interventions

PROCEDUREBlood draw/buccal swab

The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.

Sponsors

Castleman Disease Collaborative Network
CollaboratorOTHER
University of Pennsylvania
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* CD patients: Individuals of any age who are diagnosed with or suspected by a physician to have CD, including those who do have the ability to consent and those who lack the ability to consent * Related Disease: Individuals who state that they have a disease that is a Related Disease. Related Disease means autoimmune, oncology, inflammatory/lymphoproliferative disorders and infectious diseases that are similar to Castleman * Healthy Individuals: Individuals without a history of auto-immune, inflammatory, infectious disease or oncologic disorders.

Exclusion criteria

• All individuals whose medical or psychological conditions (such as a mental handicap) would, in the opinion of the Principal Investigator, compromise the subject's safety or successful participation in the study.

Design outcomes

Primary

MeasureTime frameDescription
Collect PBMCs to use for inflammatory cell profiling via FACS1 year ~Peripheral blood will be collected to isolate peripheral blood mononuclear cells (PBMCs) used to look at inflammatory cell profiling via FACS. This will tell us what specific profiles are dysregulated.
Collect PBMCs to use for cell culture experiments1 year ~Peripheral blood will be collected to isolate peripheral blood mononuclear cells (PBMCs) for cell culture experiments.

Secondary

MeasureTime frameDescription
Use peripheral blood for biochemical testing1 year ~Biochemical testing will be performed on blood samples to collect inflammatory gene expressions using qPCR, ELISA and immunoblot.
Extract DNA and RNA from tissue samples to store in biobank1 year ~Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored in our biobank for future research.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026